Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
BioTime, Inc.
Type
Public
Traded as AMEX: BTX TASE: BTX
Industry Biotechnology, regenerative medicine
Founded 1990
Headquarters Alameda, California
Key people

Michael D. West
(CEO)

Angus Russell (Director; former CEO of Shire Plc)
Website www.biotime.com

BioTime, Inc. is a clinical-stage biotechnology company in the field of regenerative medicine headquartered in Alameda, California. BioTime stock is traded on the New York Stock Exchange Market Exchange under ticker symbol BTX. BioTime focuses primarily on two areas: stem cell technology and products for use in regenerative medicine, focusing on areas such as oncology, orthopedics, blood diseases, and blood plasma volume expanders for use in surgery and treatment of traumatic injuries.

BioTime’s products currently on the market include Hextend, a blood plasma volume expander made and distributed by Hospira and research reagents. Hospira was acquired by Pfizer in February 2015.

The company is in clinical trials for age-related macular degeneration (AMD). On November 3, 2014 BioTime's subsidiary Cell Cure Neurosciences announced they had received FDA authorization to initiate a phase I/IIa trial of OpRegen, an embryonic stem cell-derived treatment for the dry-AMD.

BioTime was founded in 1990 in Berkeley, California. The company initially focused on developing processes to cool living bodies, and related projects.

In 2007, the company appointed Michael D. West, Ph.D, as chief executive officer. West had been CSO and CEO of Advanced Cell Technology (and prior to that had founded Geron (NASDAQ: GERN), for which he secured venture capital investment from Kleiner Perkins Caufield & Byers and Venrock.

Also in 2009, BioTime secured $4.72 million in grant funding from the California Institute for Regenerative Medicine (CIRM) to expand its "ACTCellerate" program, which it had acquired the previous year from Advanced Cell Technology for $250,000 plus royalties.

In October 2010, BioTime entered a license agreement with Teva (NYSE: TEVA) to develop and market BioTime's OpRegen for the treatment of age-related macular degeneration, an effort that in 2013 received $1.5 million in funding from Israel's Office of the Chief Scientist.

In 2013, BioTime acquired the stem-cell assets of Geron Corporation, with the aim of restarting its embryonic stem cell-based clinical trial for spinal cord injury.

BioTime has a number of subsidiaries, including:

BioTime’s Board of Directors includes:

Investment goal date:
Dividends reinvested
BioTime, Inc. BTX report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-09
--
--
Q4 2017
2018-03-14
--
--
Q3 2017
2017-11-09
--
--
Q3 2017
2017-11-09
0.1200
0.0000
Q2 2017
2017-08-02
-0.1100
-0.1100
Q1 2017
2017-05-10
0.4600
0.4600
Q4 2016
2017-03-16
-0.0500
-0.0500
Q3 2016
2016-11-03
0.3000
0.3000
Q2 2016
2016-08-09
0.2600
0.2600
Q1 2016
2016-05-10
-0.1900
-0.1900
Q4 2015
2016-03-15
-0.1600
-0.1600
Q3 2015
2015-11-09
0.0000
-0.1800
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Bank of New York Mellon Corp
445031
BlackRock Fund Advisors
2247046
BlackRock Inc.
4901298
BlackRock Institutional Trust Company, N.A.
2051289
BlackRock Investment Management, LLC
278470
BROADWOOD CAPITAL INC
24897032
Destination Wealth Management
591245
GEODE CAPITAL MANAGEMENT, LLC
1043378
Manatuck Hill Partners, LLC
620350
NORTHERN TRUST CORP
888870
Prescott General Partners LLC
1851851
STATE STREET CORP
1219546
TIAA CREF INVESTMENT MANAGEMENT LLC
177457
Vanguard Group, Inc
3146178
Veritable, L.P.
155125
Major Shareholders
Name Relationship
Total Shares
Holding stocks
BIOTIME INC
29.6100% (21823340)
BTX /
GREENBELT CORP /NY
2.6700% (1968505)
BTX /
GREENWAY PARTNERS L P
0.5100% (375351)
BTX /
DUBERSTEIN GARY K
0.0200% (12936)
BTX /
SEGALL JUDITH
0.8100% (594645)
BTX /
SEINBERG STEVEN A
0.0300% (22500)
BTX /
FARRELL STEPHEN C
0.1300% (97450)
BTX / QCOR / STAA /
GARCIA PETER S
0.0100% (7000)
BTX / MRNA / PDLI /
BURNS ARNOLD I
0.0200% (15000)
BTX /
WEST MICHAEL D
1.2000% (883839)
BTX /
KINGSLEY ALFRED D
7.4400% (5481555)
BTX /
SCHLACHET DAVID
0.0400% (32050)
BTX /
COHEN ABRAHAM E
0.0100% (10000)
BTX / MNKD /
BROADWOOD PARTNERS LP
40.6700% (29971561)
BTX / QCOR / STAA /
BRADSHER NEAL C
0.0900% (62908)
BTX / QCOR /
Peabody Robert
0.4300% (315777)
BTX /
Cartt Stephen LaHue
0.2100% (155125)
BTX / QCOR /
ANDREWS DEBORAH J
0.0100% (8396)
BTX / STAA /
LICHTINGER PEDRO
0.1700% (126250)
BTX /
Russell Angus C.
0.0900% (67500)
MOHANTY ADITYA P.
0.1300% (92622)
BTX /
% ()